A Novel Antioxidant Multitarget Iron Chelator M30 Protects Hepatocytes against Ethanol-Induced Injury

Figure 4

M30 improved cellular inflammation and NLRP3 inflammasome activation. (a, b) Changes of secreted levels of TNF-α and IL-6 in each group after treatments. (c) Change of transcriptional activity of NF-κB p65 subunit after treatments. (d) Expressional changes of NLRP3, ASC, and caspase-1 proteins after treatments. (e, f) Changes of secreted levels of IL-1β and IL-18 in each group after treatments. Data from each group () were expressed as means ± SEM. Statistical comparison between groups was done using the Kruskal-Wallis test followed by Dunn’s post hoc test to detect differences in all groups. “” means significantly different from control group (). “” means significantly different from control group (). “” means significantly different from control group (). “” means significantly different from ethanol exposure group (). “” means significantly different from ethanol exposure group (). “” means significantly different from ethanol exposure group (). Letters “a” labelled above the values of control, M30, and ethanol + M30 groups mean there is no significant change among these groups (). Letter “b” means the value of ethanol-treated group is statistically different from other three values (). For NLRP3 protein, letter “c” on ethanol + M30 group means significant change when compared with other three groups (i.e., control, ethanol, and M30, ). EtOH, ethanol, M30, vehicle M30 treatment, E + M30, ethanol + M30 cotreatment.

(a)

(b)

(c)

(d)

(e)

(f)